[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2008009886A - Anticuerpos que enlazan par-2. - Google Patents

Anticuerpos que enlazan par-2.

Info

Publication number
MX2008009886A
MX2008009886A MX2008009886A MX2008009886A MX2008009886A MX 2008009886 A MX2008009886 A MX 2008009886A MX 2008009886 A MX2008009886 A MX 2008009886A MX 2008009886 A MX2008009886 A MX 2008009886A MX 2008009886 A MX2008009886 A MX 2008009886A
Authority
MX
Mexico
Prior art keywords
antibodies
par
derivatives
polypeptides
methods
Prior art date
Application number
MX2008009886A
Other languages
English (en)
Inventor
George Duke Virca
Shaw-Fen Sylvia Hu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2008009886A publication Critical patent/MX2008009886A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona composiciones y métodos con relación a o derivado de los anticuerpos anti-PAR-2. En modalidades particulares, la invención proporciona anticuerpos que unen PAR-2 humano, fragmentos y derivados que enlazan a PAR-2 de tales anticuerpos, y polipéptidos que enlazan a PAR-2 comprenden tales fragmentos. Otras modalidades proporcionan ácidos nucleicos que codifican tales anticuerpos, fragmentos y derivados de anticuerpo y polipéptidos, las células comprenden tales polinucleótidos, métodos de hacer tales anticuerpos, fragmentos y derivados de anticuerpo y polipéptidos, y métodos para usar tales anticuerpos, fragmentos y derivados de anticuerpo y polipéptidos, que incluyen métodos de tratar o diagnosticar, a sujetos que tienen trastornos o condiciones relacionados con PAR-2.
MX2008009886A 2006-02-10 2007-02-09 Anticuerpos que enlazan par-2. MX2008009886A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77245606P 2006-02-10 2006-02-10
PCT/US2007/003796 WO2007092640A2 (en) 2006-02-10 2007-02-09 Antibodies that bind par-2

Publications (1)

Publication Number Publication Date
MX2008009886A true MX2008009886A (es) 2008-10-23

Family

ID=38345850

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008009886A MX2008009886A (es) 2006-02-10 2007-02-09 Anticuerpos que enlazan par-2.

Country Status (8)

Country Link
US (3) US7888482B2 (es)
EP (1) EP1981913B1 (es)
JP (1) JP5255453B2 (es)
AU (1) AU2007212195B2 (es)
CA (1) CA2638849C (es)
ES (1) ES2476892T3 (es)
MX (1) MX2008009886A (es)
WO (1) WO2007092640A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
EP2215474A4 (en) * 2007-07-16 2012-07-18 Avaxia Biologics Inc ANTIBODY THERAPY FOR MODULATING THE FUNCTION OF DARM RECEPTORS
CA2734139C (en) 2007-10-02 2019-12-24 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
EP2313110A1 (en) * 2008-08-05 2011-04-27 Boehringer Ingelheim International GmbH Effectors of par-2 activation and their use in the modulation of inflammation
WO2010132954A1 (en) * 2009-05-21 2010-11-25 Oral Health Australia Pty Ltd Method of treating periodontal disease by administering antagonists of par-2
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
MY162557A (en) 2010-02-26 2017-06-15 Oral Health Australia Pty Ltd Treatment or prevention of infection
WO2012077105A2 (en) * 2010-12-07 2012-06-14 Bio-Marcare Technologies Ltd. Biomarkers for detecting a cancerous state in a subject
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
US11427627B2 (en) 2013-09-05 2022-08-30 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
JP2016531864A (ja) 2013-09-25 2016-10-13 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｐａｒ−２シグナル伝達経路の阻害剤として有用なイミダゾピリダジン
EP3467501B1 (en) 2014-05-16 2020-11-04 Amgen Inc. Assay for detecting th1 and th2 cell populations
CA3056011A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CA3088557C (en) * 2018-02-09 2024-02-27 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
JP2021519068A (ja) 2018-03-26 2021-08-10 アムジェン インコーポレイテッド 細胞培養において産生される抗体の総非フコシル化グリコフォーム
EP3946332A1 (en) 2019-04-05 2022-02-09 Université de Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
PE20231187A1 (es) 2020-08-18 2023-08-15 Cephalon Llc Anticuerpos anti-par-2 y metodos de uso de los mismos
CN112229996A (zh) * 2020-08-25 2021-01-15 深圳市第二人民医院(深圳市转化医学研究院) 蛋白酶激活受体2作为宫颈癌转移检测标志物的应用
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
MX2023014515A (es) 2021-06-07 2024-01-29 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilacion de proteinas glucosiladas.
EP4413377A1 (en) 2021-10-05 2024-08-14 Amgen Inc. Fc-gamma receptor ii binding and glycan content
GB202204159D0 (en) * 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874400A (en) 1993-07-26 1999-02-23 Cor Therapeutics Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor
US5629174A (en) 1993-07-26 1997-05-13 Cor Therapeutics, Inc. Recombinant C140 receptor
AU5895500A (en) * 1999-06-29 2001-01-31 Cor Therapeutics, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
WO2001052883A1 (en) 2000-01-20 2001-07-26 Amgen Inc. Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics
WO2004080373A2 (en) 2003-03-11 2004-09-23 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
EP2313110A1 (en) 2008-08-05 2011-04-27 Boehringer Ingelheim International GmbH Effectors of par-2 activation and their use in the modulation of inflammation

Also Published As

Publication number Publication date
JP2009525758A (ja) 2009-07-16
US7888482B2 (en) 2011-02-15
US20110165171A1 (en) 2011-07-07
AU2007212195B2 (en) 2012-02-02
US8287872B2 (en) 2012-10-16
EP1981913A2 (en) 2008-10-22
JP5255453B2 (ja) 2013-08-07
CA2638849C (en) 2014-07-08
ES2476892T3 (es) 2014-07-15
US20130189281A1 (en) 2013-07-25
WO2007092640A3 (en) 2008-01-10
WO2007092640A2 (en) 2007-08-16
CA2638849A1 (en) 2007-08-16
AU2007212195A1 (en) 2007-08-16
US20070237759A1 (en) 2007-10-11
EP1981913B1 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
MX2008009886A (es) Anticuerpos que enlazan par-2.
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
PH12012501006A1 (en) Compositions and methods relating to anti-igf-1 receptor antibodies
MX2009002571A (es) Anticuerpos anti-activina a y usos de los mismos.
UA96139C2 (uk) Антитіло до нейропіліну-1 (nrp1)
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
WO2013192596A3 (en) Antigen binding proteins that bind ccr2
WO2008108986A3 (en) Methods and compositions for treating tumor diseases
TW200745163A (en) Peptides that block the binding of IgG to FcRn
MX353319B (es) Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
WO2008077945A3 (en) Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
MY153751A (en) Antibodies directed to her-3 and uses thereof
WO2004013180A3 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
MY163032A (en) Human anti-il-23 antibodies, compositions, methods and uses
WO2007111661A3 (en) Human antibodies specific for gastrin materials and methods
WO2007075915A3 (en) Monoclonal antibodies against orthopoxviruses
WO2009139853A3 (en) Human monoclonal antibodies against human chemokine receptor ccr7
WO2010031749A9 (en) Compositions and methods for detecting tlr3
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
WO2008109533A3 (en) Human antibodies that bind multiple irta family proteins, and uses thereof
WO2006029176A3 (en) Cancer-testis antigens
WO2004066933A3 (en) Compositions and methods for treating cancer using igsf9 and liv-1
WO2013191982A3 (en) Antigen binding proteins that bind igf1r

Legal Events

Date Code Title Description
FG Grant or registration